Cellectis (NASDAQ:CLLS) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday.

A number of other research firms also recently weighed in on CLLS. Oppenheimer boosted their target price on Cellectis from $40.00 to $44.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 12th. Zacks Investment Research downgraded Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Barclays began coverage on Cellectis in a research report on Monday, July 16th. They issued an “overweight” rating and a $50.00 target price for the company. Finally, ValuEngine downgraded Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $44.33.

NASDAQ:CLLS opened at $28.16 on Tuesday. The company has a market capitalization of $1.13 billion, a P/E ratio of -10.13 and a beta of 1.83. Cellectis has a 1-year low of $22.62 and a 1-year high of $38.85.

Cellectis (NASDAQ:CLLS) last released its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.45. The company had revenue of $8.34 million during the quarter, compared to the consensus estimate of $9.43 million. Cellectis had a negative return on equity of 25.46% and a negative net margin of 281.38%. analysts expect that Cellectis will post -2.15 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Cellectis by 18.0% in the second quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock valued at $119,949,000 after purchasing an additional 647,164 shares during the last quarter. Bain Capital Public Equity Management LLC bought a new stake in Cellectis in the second quarter valued at approximately $3,098,000. Millennium Management LLC lifted its position in Cellectis by 223.1% in the second quarter. Millennium Management LLC now owns 145,563 shares of the biotechnology company’s stock valued at $4,118,000 after purchasing an additional 100,515 shares during the last quarter. Nexthera Capital LP lifted its position in Cellectis by 64.7% in the second quarter. Nexthera Capital LP now owns 548,212 shares of the biotechnology company’s stock valued at $15,509,000 after purchasing an additional 215,458 shares during the last quarter. Finally, Adalta Capital Management LLC bought a new stake in Cellectis in the second quarter valued at approximately $620,000. Institutional investors own 27.11% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Recommended Story: Technical Analysis of Stocks, How Can It Help

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.